Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19
A Phase 3 Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients With Severe and Critical COVID-19 Pneumonia
Sponsor: Humanigen, Inc.
This PHASE3 trial investigates Coronavirus Disease 2019 (COVID-19) Pneumonia and is currently ongoing. Humanigen, Inc. leads this study, which shows 11 recorded versions since 2020 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Apr 2023 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Apr 2021 — Apr 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
▶ Show 6 earlier versions
-
Feb 2021 — Apr 2021 [monthly]
Recruiting PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE3
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Jul 2020 — Sep 2020 [monthly]
Recruiting PHASE3
-
Jun 2020 — Jul 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
May 2020 — Jun 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Humanigen, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .